Redefining ILD Through Precision Medicine: Using Biomarkers to Identify Progression & Underlying Disease Drivers
- Moving beyond broad disease labels to a molecular understanding of ILD, exploring how multi-omic and biomarker-driven approaches are beginning to define patient subtypes based on underlying biology rather than clinical classification alone
- Advancing strategies to identify patients at risk of progression, including how circulating biomarkers, imaging, and molecular signatures can be integrated to predict disease trajectory and enable earlier, more confident intervention
- Interrogating the “lumping vs splitting” debate in ILD and PPF, and what a precision medicine framework means for patient stratification, clinical trial design, and the future development of targeted therapies